A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes

被引：0

作者：

Kosei Kimura

Mitsuhiko Iwamoto

Satoru Tanaka

Daigo Yamamoto

Katsuhide Yoshidome

Hiroyuki Ogura

Risa Terasawa

Nobuki Matsunami

Yuko Takahashi

Toshikatsu Nitta

Takashi Morimoto

Hiroya Fujioka

Kanako Kawaguchi

Kazuhisa Uchiyama

机构：

[1] Osaka Medical College Hospital,Department of Breast and Endocrine Surgery

[2] National Hospital Organization Osaka Minami Medical Center,Department of Breast Surgery

[3] Kansai Medical University Medical Center,Department of Breast Surgery

[4] Osaka Police Hospital,Department of Breast and Endocrine Surgery

[5] Hamamatsu University School of Medicine,Department of Breast Surgery

[6] Osaka Rosai Hospital,Department of Breast Surgery

[7] Hirakata City Hospital,Department of Breast and Endocrine Surgery

[8] Medico Shunju Shiroyama Hospital Breast Center,Division of Surgery

[9] Yao Municipal Hospital,Department of Breast Surgery

来源：

Cancer Chemotherapy and Pharmacology | 2018年 / 81卷

关键词：

Eribulin; Metastatic breast cancer; First or second-line; Objective response rate; QOL;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：923 / 933

页数：10

共 50 条

[1] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
Kimura, Kosei
Iwamoto, Mitsuhiko
Tanaka, Satoru
Yamamoto, Daigo
Yoshidome, Katsuhide
Ogura, Hiroyuki
Terasawa, Risa
Matsunami, Nobuki
Takahashi, Yuko
Nitta, Toshikatsu
Morimoto, Takashi
Fujioka, Hiroya
Kawaguchi, Kanako
Uchiyama, Kazuhisa
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 923 - 933
[2] A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
Takashima, Tsutomu
Tokunaga, Shinya
Tei, Seika
Nishimura, Shigehiko
Kawajiri, Hidemi
Kashiwagi, Shinichiro
Yamagata, Shigehito
Noda, Satoru
Nishimori, Takeo
Mizuyama, Yoko
Sunami, Takeshi
Tezuka, Kenji
Ikeda, Katsumi
Ogawa, Yoshinari
Onoda, Naoyoshi
Ishikawa, Tetsuro
Kudoh, Shinzoh
Takada, Minoru
Hirakawa, Kosei
SPRINGERPLUS, 2016, 5 : 1 - 8
[3] Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
Hayashida, Tetsu
Jinno, Hiromitsu
Mori, Katsuaki
Sato, Hiroki
Matsui, Akira
Sakurai, Takashi
Hattori, Hiroaki
Takayama, Shin
Wada, Masahiro
Takahashi, Maiko
Seki, Hirohito
Seki, Tomoko
Nagayama, Aiko
Matsumoto, Akiko
Kitagawa, Yuko
BMC CANCER, 2018, 18
[4] Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
Tetsu Hayashida
Hiromitsu Jinno
Katsuaki Mori
Hiroki Sato
Akira Matsui
Takashi Sakurai
Hiroaki Hattori
Shin Takayama
Masahiro Wada
Maiko Takahashi
Hirohito Seki
Tomoko Seki
Aiko Nagayama
Akiko Matsumoto
Yuko Kitagawa
BMC Cancer, 18
[5] Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study
Ortega, Vanesa
Anton, Antonio
Garau, Isabel
Afonso, Nomia
Calvo, Lourdes
Fernandez, Yolanda
Martinez-Garcia, Maria
Blanco, Esperanza
Zamora, Pilar
Garcia, Mirta
Juan Illarramendi, Jose
Rodriguez Sanchez, Csar Augusto
Sampayo, Miguel
Aguirre, Elena
Manuel Perez-Garcia, Jose
Cortes, Javier
Llombart-Cussac, Antonio
CLINICAL BREAST CANCER, 2019, 19 (02) : 105 - 112
[6] Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
Kenjiro Aogi
Kenichi Watanabe
Masahiro Kitada
Takafumi Sangai
Shoichiro Ohtani
Tomoyuki Aruga
Hidetoshi Kawaguchi
Tomomi Fujisawa
Shigeto Maeda
Takashi Morimoto
Nobuaki Sato
Shintaro Takao
Satoshi Morita
Norikazu Masuda
Masakazu Toi
Shinji Ohno
International Journal of Clinical Oncology, 2021, 26 : 1229 - 1236
[7] Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
De Angelis, C.
Bruzzese, D.
Bernardo, A.
Baldini, E.
Leo, L.
Fabi, A.
Gamucci, T.
De Placido, P.
Poggio, F.
Russo, S.
Forestieri, V
Lauria, R.
De Santo, I
Michelotti, A.
Del Mastro, L.
De Laurentiis, M.
Giuliano, M.
De Placido, S.
Arpino, G.
ESMO OPEN, 2021, 6 (02)
[8] First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
Hardy-Bessard, Anne-Claire
Brocard, Fabien
Clatot, Florian
Lortholary, Alain
You, Benoit
Grenier, Julien
Martin-Babau, Jerome
Lucas, Brigitte
Meunier, Jerome
Ferrero, Jean-Marc
Savoye, Aude-Marie
Marti, Adina
Despax, Raymond
Moullet, Isabelle
Emile, George
BREAST, 2020, 54 : 256 - 263
[9] Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Park, Yeon Hee
Im, Seock-Ah
Kim, Sung-Bae
Sohn, Joo Hyuk
Lee, Keun Seok
Chae, Yee Soo
Lee, Ki Hyeong
Kim, Jee Hyun
Im, Young-Hyuck
Kim, Ji-Yeon
Kim, Tae-Yong
Lee, Kyung-Hun
Ahn, Jin-Hee
Kim, Gun Min
Park, In Hae
Lee, Soo Jung
Han, Hye Sook
Kim, Se Hyun
Jung, Kyung Hae
EUROPEAN JOURNAL OF CANCER, 2017, 86 : 385 - 393
[10] Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
Inoue, Kenichi
Ninomiya, Jun
Saito, Tsuyoshi
Okubo, Katsuhiko
Nakakuma, Takashi
Yamada, Hirofumi
Kimizuka, Kei
Higuchi, Tohru
INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 538 - 547

← 1 2 3 4 5 →